Instrumento Inactivo

Otros idiomas Theravance Inc Nasdaq

Acciones

US88338T1043

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

08/05	Innoviva, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
24/04	Los datos positivos de la fase 3 de zoliflodacina oral para el tratamiento de la gonorrea no complicada de la filial Innoviva Specialty Therapeutics, Inc. se anuncian en ESCMID Global 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Innoviva: Q1 Earnings Snapshot	08/05
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M	08/05
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress	08/05
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Innoviva to Participate in the BofA Securities Health Care Conference	08/05
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	25/04
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	29/02
Innoviva: Q4 Earnings Snapshot	29/02
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	29/02
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	29/02
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	06/02
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	06/02
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	17/11
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	02/11
Innoviva: Q3 Earnings Snapshot	01/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Theravance Inc Nasdaq

Acciones

US88338T1043

Otros idiomas

Filtros